
Mircera50 µg
Radiant Pharmaceuticals Ltd.
Epoetin Beta [Methoxy Polyethyelene Glycol] is a long-acting erythropoiesis-stimulating agent (ESA), also known as pegylated epoetin beta or methoxy polyethylene glycol-epoetin beta (C.E.R.A.) and more.
Epoetin Beta [Methoxy Polyethyelene Glycol] is a long-acting erythropoiesis-stimulating agent (ESA), also known as pegylated epoetin beta or methoxy polyethylene glycol-epoetin beta (C.E.R.A.), used for the following indication:
Epoetin Beta [Methoxy Polyethyelene Glycol] is intended to reduce the need for red blood cell transfusions in appropriately selected patients, not to normalize hemoglobin levels.
Before initiating Epoetin Beta [Methoxy Polyethyelene Glycol], evaluate iron status; all patients should have adequate iron stores. Correct or exclude other causes of anemia (e.g., vitamin deficiency, hemolysis, bleeding) before treatment. Use the lowest dose sufficient to reduce the need for red blood cell transfusion.
| Population | Starting Dose | Maintenance/Notes |
|---|---|---|
| Adult CKD on dialysis (ESA-naive) | 0.6 mcg/kg IV or SC once every 2 weeks | May convert to once-monthly dosing at twice the biweekly dose once hemoglobin is stable |
| Adult CKD not on dialysis (ESA-naive) | 0.6 mcg/kg IV or SC once every 2 weeks, or 1.2 mcg/kg SC once monthly | Titrate based on hemoglobin response |
| Conversion from another ESA | Dose calculated from prior weekly ESA dose per approved conversion table | Administer once every 2 weeks initially |
Do not increase the dose more than once every 4 weeks. If hemoglobin rises rapidly (more than 1 g/dL in any 2-week period), reduce the dose by at least 25%. Withhold dosing if hemoglobin exceeds the level needed to avoid transfusion. See Dosage and Administration sections for further detail, and Precautions and Warnings for hemoglobin target guidance.
The most commonly reported adverse reactions with Epoetin Beta [Methoxy Polyethyelene Glycol] include:
Serious but less common reactions include serious allergic/hypersensitivity reactions, and the boxed-warning risks (cardiovascular events, thrombosis, tumor progression) described under Precautions and Warnings.
Epoetin Beta [Methoxy Polyethyelene Glycol] is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.